Abstract. There is no vaccine to prevent dengue fever, a mosquito-borne viral disease, caused by four serotypes of dengue viruses. In this study, which has been prompted by the emergence of dengue virus envelope domain III as a promising sub-unit vaccine candidate, we have examined the possibility of developing a chimeric bivalent antigen with the potential to elicit neutralizing antibodies against two serotypes simultaneously. We created a chimeric dengue antigen by splicing envelope domain IIIs of serotypes 2 and 4. It was expressed in Escherichia coli and purified to near homogeneity. This protein retains the antigenic identitities of both its precursors. It elicited antibodies that could efficiently block host cell binding of both serotypes 2 and 4 of dengue virus and neutralize their infectivity (neutralizing antibody titers approximately 1:40 and ∼1:80 for dengue virus serotypes 2 and 4, respectively). This work could be a forerunner to the development of a single envelope domain III-based tetravalent antigen.
INTRODUCTION
Dengue fever, a mosquito-borne viral disease, has become a major worldwide public health problem, with a dramatic expansion in recent decades. Globally, approximately a hundred million cases of dengue infections are believed to occur each year, with approximately half a million of these resulting in potentially fatal dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). Currently, the number of people estimated to be at risk of dengue infections is approximately 2.5 billion. 1, 2 This is predicted to register almost a 100% increase in the coming 2-3 decades. 3 There are four antigenically closely related, but distinct, serotypes of dengue (DEN) viruses designated DEN-1, -2, -3, and -4, which are members of the family Flaviviridae. 4 Laboratory and epidemiologic data suggest that prior infection with one serotype, although conferring lifelong homologous immunity to that serotype, 5 can sensitize an individual to DHF/DSS during a secondary infection with any of the remaining three serotypes through an antibody-dependent enhancement (ADE) mechanism. 6 This, in conjunction with other host-as well virusrelated factors, appears to contribute to disease pathogenesis. 7 A dengue vaccine has remained elusive despite decades of effort. An ideal dengue vaccine must be tetravalent, capable of affording protection against infection by all four serotypes. This consideration, together with the lack of a suitable animal model of the disease, has made the development of dengue vaccines a challenging task. 8 Although early efforts to develop dengue vaccines have focused on conventional approaches, 9 recent initiatives focus predominantly on recombinant strategies. 10, 11 Several recombinant strategies, based on infectious clone technology, [12] [13] [14] DEN antigen-encoding viral [15] [16] [17] and plasmid [18] [19] [20] vectors, and recombinant DEN antigens, produced using Escherichia coli, [21] [22] [23] [24] [25] yeast, [25] [26] [27] [28] and insect cell 29, 30 -based heterologous expression systems, are being explored.
The major envelope (E) protein of DEN viruses is considered a lead sub-unit dengue vaccine candidate and virtually all recombinant dengue vaccine approaches are focused on it. The E protein is a large (approximately 500 amino acid residues), cysteine-rich (12 highly conserved cysteine residues forming six S-S bonds), multifunctional protein. It is involved in several critical aspects of DEN virus biology such as receptor recognition, membrane fusion, and virion morphogenesis, 4, 31 and has been implicated in the generation of neutralizing antibodies and the induction of protective immunity. 15, 32 It is responsible for eliciting the first and longest-lasting antibody response to dengue infection 33 because it contains multiple, serotype-specific, conformation-dependent, neutralizing epitopes. [34] [35] [36] [37] Recent crystallographic studies have shown that the E protein of DEN viruses is a complex molecule organized into three distinct domains, a central domain (I), a dimerization domain (II), and an immunoglobulin-like domain (III). [38] [39] [40] Several lines of evidence accumulated in recent years have identified domain III of the E protein (referred to here as EDIII) as the critical region from the perspective of vaccine development. EDIII-spanning amino acid residues 300-400 of the E protein is a highly stable, independently folding domain 41 that lies exposed and accessible on the virion surface. 42 Multiple type-and subtype-specific neutralizing epitopes of the E protein have been mapped to EDIII. [34] [35] [36] [37] A variety of studies have implicated this domain in host receptor-binding. 24, 34, 41, 43 Immunization of animals with either EDIII-encoding plasmids 18 or chimeric proteins containing EDIII fused to maltose-binding protein (MBP) has been shown to elicit neutralizing antibodies to DEN viruses. 22, 44 Importantly, these studies also showed that EDIII has a low potential for inducing cross-reactive antibodies to heterologous DEN serotypes. 22 We recently demonstrated that the EDIII of DEN-2 could be successfully expressed in high yields in E. coli without the aid of an MBP carrier. Furthermore, we also showed that the in vitro-refolded protein was biologically functional on the basis of its ability to block the binding of DEN-2 virus to baby hamster kidney (BHK) cells. 23 The EDIII-MBP protein studies referred to are based on generating a tetravalent dengue vaccine by physically mixing four monovalent (i.e., single serotype specific) EDIII-MBPs. 44 The current work is based on the premise that the development of a single tetravalent EDIII-based chimeric protein, rather than four monovalent EDIIIs, may offer a simpler and inexpensive alternative. As a first step in examining the feasibility of developing such a chimeric protein, we have spliced EDIIIs of two DEN serotypes (DEN-2 and DEN-4) by means of a flexible peptide linker, to create a novel bivalent antigen, rEDIII-4/2. We used this bivalent protein to address the following questions. 1) Would it retain the antigenic identity of its monovalent precursors? 2) Would it elicit antibodies specific to each of its constituent serotypes? 3) Would these antibodies be effective in recognizing and neutralizing the infectivitiy of DEN-2 and DEN-4 viruses? In this report, we describe the creation of the bivalent gene, its expression in E. coli, the purification of the expressed bivalent protein, and preliminary proof-of-concept data in support of its potential to function as a bivalent dengue antigen.
MATERIALS AND METHODS

Materials.
Escherichia coli host strain DH5␣ for routine recombinant plasmid manipulations was obtained from Invitrogen (Carlsbad, CA). The E. coli host strain SG13009 for recombinant protein expression was obtained from Qiagen (Hilden, Germany). The expression plasmid pQE60 (amp r ), Ni-NTA superflow resin, HisSorb enzyme-linked immunosorbent assay (ELISA) microtiter well strips, and anti-His monoclonal antibody (MAb) (catalog no. 34660) were also obtained from Qiagen. Plasmid pGEMT-Easy for TA cloning was obtained from Promega (Madison, WI). The MAb specific for DEN-2 virus (3H5) was obtained from the American Type Culture Collection (Manassas, VA). The DEN-4 virusspecific MAb (catalog no. MAB8704) was obtained from Chemicon International, Inc., Temecula, CA). The secondary antibody-enzyme conjugates (anti-mouse IgG-alkaline phosphatase [AP], anti-mouse IgG-horseradish peroxidase [HRPO] , and anti-mouse IgG-fluorescein isothiocyanate [FITC] conjugate) and the AP substrate 5-bromo-4-chloro-3-indolyl phosphate/nitroblue tetrazolium (BCIP/NBT) were obtained from Calbiochem (San Diego, CA). The HRPO substrate 3, 3Ј, 5, 5Ј-tetramethylbenzidine (TMB) was obtained from Kirkegaard and Perry Laboratories, Gaithersburg, MD).
The DEN-2 (NGC strain) and DEN-4 (H241 Dominican strain) viruses were kindly provided by Dr. A. Falconar (University of Oxford, Oxford, United Kingdom). BHK 21 cells, monkey cell line LLCMK2, mosquito cell line, C6/36, and the 3H5 MAb-producing hybridoma cell line HB46 were obtained from the American Type Culture Collection. All of these cell lines, with the exception of C6/36, were maintained in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% (v/v) heat-inactivated fetal calf serum (FCS), in a humidified 10% CO 2 incubator at 37°C. The C6/ 36 cells were maintained in Leibovitz L-15 medium supplemented with tryptose phosphate broth (2% v/v) and 10% (v/v) ⌬FCS in a CO 2 -free incubator at 28°C. The QIAmp viral RNA mini kit was obtained from Qiagen and the reverse transcription-polymerase chain reaction (RT-PCR) Titan One Tube RT-PCR system was from obtained from Roche Diagnostics (Mannheim, Germany).
Isolation of EDIII-encoding cDNAs. Tissue culture supernatants obtained from C6/36 cells that were infected separately with either DEN-2 or DEN-4 virus (at low multiplicity) served as the starting material for the isolation of viral genomic RNAs, using the commercially available QIAmp viral RNA mini kit. The viral RNAs were incorporated as templates in the RT-PCR to obtain the recombinant EDIIIencoding cDNAs designated as EDIII-2 and EDIII-4 genes, which corresponded to DEN serotypes 2 and 4, respectively. The EDIII-specific primers used in the RT-PCRs are shown in Table 1 . Both of these genes are approximately 0.38 kilobases, and each is predicted to encode 121 amino acid residues corresponding to amino acids 296-416 (encompassing EDIII and spanning amino acids 300-400) of the E molecule. Since each of these two genes encode recombinant EDIII of a single DEN serotype (either DEN-2 or DEN-4), they are referred to as monovalent. These genes were engineered to have a Bgl II site at the 5Ј end and a Bam HI site at the 3Ј end to facilitate head-to-tail fusion with each other, as well as cloning into the E. coli expression plasmid pQE60. The RT-PCR-generated monovalent genes were purified, A-tailed using Taq polymerase, and ligated into the TA cloning site of the plasmid pGEMT-Easy to create the monovalent constructs pT-2 (harboring the monovalent gene EDIII-2) and pT-4 (harboring the monovalent gene EDIII-4). The ligated products were transformed into E. coli DH5␣ cells. The resultant transformants were selected on ampicillin plates and subjected to preliminary PCR screening using insert-specific primers. The PCR-positive clones were subjected to restriction analysis. Selected clones were further screened by in vitro coupled transcription and translation (T N T) using T7 RNA polymerase as previously described 45 to identify those with intact open reading frames. One clone each of pT-2 and pT-4 was sequenced. No errors were seen in the EDIII-4 cDNA. However, the EDIII-2 cDNA had two point mutations, resulting in Ile to Phe (amino acid 402) and Thr to Ala (amino acid 404) substitutions. Since both of these were conservative changes, and outside domain III, they were ignored.
Creation of the bivalent gene EDIII-4/2. The monovalent genes EDIII-2 and EDIII-4 (carried by plasmids pT-2 and pT-4, respectively), were verified to be expressed in E. coli and then used as precursors to create the chimeric bivalent gene EDIII-4/2. To create this chimeric gene, which was composed of EDIIIs of two DEN serotypes (DEN-2 and DEN-4 in this case), the EDIII-2 gene was isolated from pT-2 by Bgl II/Bam HI double digestion and ligated into the Bam HI site of pT-4 to generate the construct pT-4/2. Once again, DH5␣ transformants were screened by PCR, restriction, T N T, and sequence analyses to choose the right bivalent clone. In the fusion gene EDIII-4/2 present in the pT-4/2 construct, the two monovalent genes are joined in-frame through ligation of Bam HI site (at the 3Ј end of EDIII-4 gene) to Bgl II site (at the 5Ј end of the EDIII-2 gene) with concomitant loss of both sites. As a result, the bivalent gene is also flanked by Bgl II site on the 5Ј side and Bam HI site at the 3Ј end, similar to the monovalent genes.
Construction of bivalent E. coli expression plasmid vector. The bivalent EDIII-4/2 gene was cloned into the bacterial expression vector pQE-60 under the control of the isopropylthiogalactoside (IPTG)-inducible PT5/lac O promoter. To this end, the recombinant bivalent gene was isolated from plasmid pT-4/2 as a Bgl II/Bam HI fragment and ligated to pQE60 that had been digested with these same enzymes. In the resulting construct, pQ-EDIII-4/2, the inserted gene is fused in-frame with the ATG codon (at the 5Ј end) and 6× His tag-encoding sequence (at the 3Ј end) provided by the pQE-60 vector. This in-frame fusion would add 11 vector-derived amino acid residues to the bivalent protein (five and six residues at the N-and C-terminal ends, respectively). Insertion of the bivalent gene in the sense orientation was designed to abolish both Bam HI and Bgl II sites in the resultant construct. Recombinant clones were selected on ampicillin plates and subjected to direct colony PCR screening using insertspecific primers, followed by restriction analysis to identify recombinants harboring the inserted gene in the sense orientation.
Expression screening of clones harboring the bivalent fusion gene. Minipreps of plasmid pQ-EDIII-4/2 isolated from the DH5␣ recombinant were used to transform the E. coli expression host strain SG13009 containing the pREP4 plasmid. The pREP4 plasmid encodes the lacI repressor (required for regulated recombinant gene expression) and the kanamycin resistance marker. Double recombinants harboring both the pQ-EDIII-4/2 and pREP4 plasmids were selected in the presence of ampicillin and kanamycin. Several of these clones were inoculated into 3-mL test tube cultures and allowed to grow at 37°C in a shaker at 200 revolutions per minute (rpm). When the cultures were in logarithmic growth phase (corresponding to an optical density [OD] of approximately 0.5-0.6 at 600 nm), they were induced with 0.5 mM IPTG for approximately four hours. After induction, equivalent number of cells from the different cultures (normalized on the basis of OD 600 values) were lysed in sample buffer and analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Uninduced controls were analyzed in parallel. One clone that expressed maximal levels of the recombinant protein was chosen for further study.
Localization of recombinant rEDIII-4/2 bivalent protein in induced cells. To determine the solubility of the recombinant bivalent protein, test tube cultures were set up and induced with 0.5 mM IPTG at log phase for four hours, and processed essentially as previously described. 23 Aliquots of the induced culture (corresponding to approximately 1.0 OD 600 ) were lysed separately using either native lysis buffer (50 mM potassium phosphate, pH 8, 0.3 M NaCl, lysozyme [1 mg/mL]) or urea lysis buffer (50 mM potassium phosphate, pH 8, 0.3 M NaCl, 8 M urea]) and separated into supernatant (S) and pellet (P) fractions by centrifugation at 15,000 × g for 10 minutes. Equivalent aliquots of all four resultant fractions were analyzed by SDS-PAGE.
Purification of the recombinant monovalent and bivalent proteins. A pre-culture was set up by inoculating 20 mL of Luria Bertani (LB) medium containing ampicillin (100 g/ mL) and kanamycin (50 g/ml) with 25 L of glycerol stock (SG13009 cells transformed with the bivalent expression vector pQ-EDIII-4/2). The culture was grown overnight in a shaker at 37°C at 200 rpm and inoculated into 0.5 liters of LB medium containing both ampicillin (100 g/mL) and kanamycin (25 g/mL) in a four-liter Haffkine flask, which was placed in the shaker and incubated at 37°C for approximately 2-3 hours at 125 rpm. When the OD 600 of the culture reached approximately 0.5-0.6 (a small aliquot of the uninduced culture was set aside for subsequent analysis by SDS-PAGE), it was induced with IPTG to a final concentration of 0.5 mM. Induction was allowed to proceed for four hours before harvesting the cells. Aliquots of the induced and uninduced cell cultures were analyzed by SDS-PAGE prior to initiating purification.
Purification of the induced protein under denaturing conditions using Ni-NTA affinity chromatography was essentially as previously described 46 with minor modifications. The induced culture was centrifuged in a Sorvall (Asheville, NC) GS3 rotor at 6,000 rpm for 15 minutes at 4°C. The cell pellet (approximately 1.5 grams wet weight) was lysed by resuspending in 50 mL of ice-cold lysis buffer (8 M urea dissolved in 100 mM sodium phosphate, pH 7.5, 0.5 M NaCl, 10 mM imidazole, 1 mM freshly added phenylmethylsulfonyl fluoride) and sonication (model 550 sonicator; Fisher Scientific, Pittsburgh, PA) for 10 minutes. We used urea rather than guanidine hydrochloride for lysis under denaturing conditions, to permit direct SDS-PAGE analysis of the samples. The lysate was stirred for two hours at 4°C and clarified by centrifugation using a Sorvall SS34 rotor (17,000 rpm for one hour at 4°C). The resultant supernatant was mixed with 4 mL of Ni-NTA Superflow resin that had been pre-equilibrated with the lysis buffer. This suspension was gently rocked overnight at 4°C and then packed into a column. After collecting the flow through, the column was washed extensively with buffers 1 (8 M urea, 0.5 M NaCl, 50 mM sodium phosphate, pH 6.3) and 2 (8 M urea, 50 mM sodium phosphate, pH 5.9) and eluted with buffer 3 (8 M urea, 50 mM sodium phosphate, pH 4.5). Fractions of 3 mL were collected for analysis. All fractions obtained during the purification were analyzed by SDS-PAGE. Relevant fractions were pooled and dialyzed against 1× phosphate-buffered saline (PBS) containing 50 mM each of arginine and glutamic acid. 47 The dialyzed protein was mixed with gentamicin to a final concentration of 50 g/mL, flash-frozen in liquid nitrogen, and stored at −80°C until use. Additionally, to help characterize the rEDIII-4/2 protein and the antibodies it can induce in terms of their serotype specificity, we also expressed and purified all four monovalent rEDIII proteins (rEDIII-1, rEDIII-2, rEDIII-3, and rEDIII-4), essentially as described for the bivalent protein.
Western blot analysis. Western blot analysis of the Ni-NTA affinity-purified bivalent recombinant protein was performed as previously described. 23 Briefly, the recombinant protein was subjected to electrophoresis under denaturing conditions (SDS-PAGE) along with relevant controls and pre-stained protein markers. Separated proteins were electrotransferred (at 100V for 1 hour at 4°C) onto a nitrocellulose membrane using the Mini Trans-blot apparatus (Bio-Rad Laboratories, Hercules, CA). The pre-stained markers allowed visualization of successful protein transfer. After overnight incubation in blocking buffer (1% polyvinylpyrrolidone [PVP], 2% bovine serum albumin, 1× PBS, pH 7.2), 0.1% Tween 20), the membrane was washed three times with 1× PBS, 0.1% Tween 20 (1× PBS-T) and incubated separately with either one of two primary antibodies for one hour at room temperature. The primary antibodies used were either the penta-His MAb (at a dilution of 1:7,500) or murine anti-rEDIII-4/2 polyclonal serum (at a dilution of 1:2,500). The blots were washed again with 1× PBS-T (three washes, 10 minutes/wash), and incubated with anti-mouse IgG-AP secondary antibody conjugate (at a dilution of 1:10,000) for 45 minutes at room temperature. The blots were washed again as above and protein bands were visualized after a 15-minute incubation at room temperature in BCIP/NBT substrate solution.
ELISA for the bivalent r-EDIII-4/2 protein and EDIIIspecific antibodies. Recombinant protein in samples before and after affinity purification on Ni-NTA matrix was analyzed using a sandwich ELISA approach 23 designed to detect only the recombinant protein. In this assay, appropriate dilutions of the 6× His-tagged recombinant protein-containing samples were coated onto commercially available Ni-NTA HisSorb microtiter wells (Qiagen). After a two-hour incubation at room temperature to allow binding, the wells were washed four times with 1× PBS-T and blocked for an additional two hours using a 5% solution of skimmed milk powder prepared in 1× PBS-T (blocking buffer). The wells were washed as before and incubated with 200 L of 3H5 MAb (1 mg/mL diluted 1:500 in blocking buffer), for one hour at room temperature. After washing as before, the wells were incubated with anti-mouse IgG-HRPO conjugate (diluted 1:10,000 in blocking buffer). After incubation for 45 minutes at room temperature, the wells were washed as before and incubated with TMB substrate for 15 minutes at 37°C. Color development was terminated by the addition of 50 L of 1M H 2 SO 4 and ODs were read at 450 nm. A negative control (all assay components minus the recombinant protein) and a blank (containing only the detection reagents) were analyzed in parallel. Since no reference standards are available, the ELISA titers obtained using the recombinant protein preparations have been expressed arbitrarily in OD units. Absorbance equivalent to 1 at 450 nm under the assay conditions is defined as 1 OD unit in this report.
The HisSorb ELISA was adapted for the detection of antibodies in the sera of immunized mice with specificity for the rEDIII proteins. In addition to the bivalent rEDIII-4/2 protein, each of the four monovalent rEDIII proteins (r-EDIII-1 to -4) were also used as capture antigens to assess the serotype specificity of different antisera. Antibody titration curves were generated and compared with serotype specificities of different antisera.
Mouse immunizations. Three BALB/c mice (4-6 weeks old) were immunized intraperitoneally with an emulsion of 25 g of rEDIII-4/2 bivalent protein in Freund's complete adjuvant. Mice were given booster immunizations twice at onemonth intervals with 20 g of the recombinant protein in Freund's incomplete adjuvant. Another group of three mice was mock-immunized in parallel using 1× PBS instead of recombinant bivalent protein. Blood was collected from each mouse on day 9 after the second booster immunization by retro-orbital bleeding. Sera were prepared and stored at −80°C until use. In parallel, we also immunized additional groups of mice (n ‫ס‬ 3) with each of the four recombinant monovalent r-EDIII proteins to raise monovalent antisera for use in characterizing the rEDIII-4/2 bivalent protein. Animal experiments were reviewed and approved by the International Centre for Genetic Engineering and Biotechnology institutional animal ethics committee and adhered to the guidelines of the Government of India.
Indirect immunofluorescence assay. BHK-21 cells seeded on coverslips were used in this experiment. The protocol used was similar to that previously reported. 16, 27 When cells were at a confluency of approximately 70% (approximately 24 hours after seeding), they were incubated with approximately 200 plaque-forming units (PFU) of DEN-2 or DEN-4 virus separately that had been pre-incubated for one hour at 37°C with 200 L of 1:50 diluted heat-inactivated (56°C for 30 minutes) murine serum. Three different murine sera were used. These were pre-immune sera, sera from mockimmunized mice, and sera from rEDIII4/2-immunized mice. Positive (cells infected with DEN-2 or DEN-4 virus without the murine serum pre-incubation step) and negative (mockinfected cells) control experiments were set up in parallel. One hour later, the cells on coverslips were rinsed three times with 1× PBS and fixed for 10 minutes with 10% formaldehyde at room temperature, followed by ice-cold methanol (prechilled to −20°C) for 20 minutes. Fixed cells were rinsed with 1× PBS and blocked with 1% PVP in 1× PBS-T for two hours at 37°C. The cells were then washed three times with 1× PBS and incubated with 200 L of primary antibody for one hour at room temperature. Two different primary antibodies were used. One was the DEN-2 virus-specific 3H5 MAb (1:300 dilution) and the other was the DEN-4 virus-specific MAb (catalog no. MAB8704 at a 1:400 dilution; Chemicon International. Inc.). Cells were then washed as before and incubated for 45 minutes with fluorescein-conjugated anti-mouse IgG (at a 1:50 dilution) at room temperature. Cells were washed and mounted in fluoroguard antifade reagent (BioRad Laboratories) to limit subsequent photo bleaching. Fluorescent cells were visualized under a Nikon (Tokyo, Japan) microscope equipped for incident illumination with a narrow band filter combination selective for FITC.
Plaque reduction neutralization test (PRNT). LLCMK2 cells were seeded at a concentration of 0.5 × 10 5 /well in 24-well plates approximately 24 hours prior to infection. Approximately 20-25 PFU each of DEN-1, DEN-2, and DEN-3, and DEN-4 viruses (50 L) were separately pre-incubated with an equal volume of serial two-fold dilutions (up to a dilution of 1:160) of heat-inactivated pooled serum collected from rEDIII-4/2-immunized mice. After overnight preincubation at 4°C, the virus/serum mixture was diluted to a final volume of 200 L with DME plus 2% ⌬FCS and used to infect a single well of 24-well plate. Each serum dilution was assayed in four replicate wells and the virus/serum preincubation mixture was prepared as a master mixture sufficient for four wells. After adsorption for two hours, the inoculum was aspirated off and the cells were overlaid with 1.25% methylcellulose in DME plus 6% ⌬FCS (1 mL/well). Appropriate controls were set up in parallel with negative control (mock-infected) wells receiving 200 L of DME plus 2% ⌬FCS and positive control wells receiving DEN-1, DEN-2, DEN-3, or DEN-4 viruses separately, pre-incubated with DME plus 2% ⌬FCS, instead of murine serum. The plates were incubated at 37°C in a humidified 5% CO 2 incubator. On day 6 post-infection, the overlay was gently decanted and the cells were fixed with 1 mL of 4% formaldehyde solution at room temperature for one hour. Wells were washed with tap water and then stained with a 1:40 diluted stock of 2% crystal violet solution in 20% ethanol for 30 minutes. Plaques revealed after staining were counted and the antiserum dilution resulting in a 50% reduction in plaque count (with reference to the number of plaques generated by the virus in the absence of antiserum), was expressed as the PRNT 50 titer.
RESULTS
Creation of EDIII-based monovalent precursorgenes.
Monovalent genes EDIII-2 and EDIII-4 encoding DEN-2 and DEN-4 virus-specific EDIIIs, respectively, were obtained as shown in Figure 1 . Before proceeding to generate the bivalent gene, we sought to investigate if these two monovalent genes can be expressed successfully in E. coli to produce the corresponding monovalent antigen proteins, which are predicted to be approximately 14 kD each. Accordingly, these genes were isolated as Bgl II/Bam HI fragments from the pT-2 and pT-4 plasmids and cloned into the E. coli expression plasmid pQE60 under the control of an inducible PT5/lac O promoter. The IPTG-mediated induction of the resultant vectors is shown in Figure 2A . A comparison of the polypeptide profiles before and after induction showed that both the EDIII-2 (lanes 2 and 3) and EDIII-4 (lanes 4 and 5) genes express a new protein of approximately 14 kD, which is consistent with the predicted size of the monovalent rEDIII-2 and rEDIII-4 proteins. The rEDIII-2 protein was expressed at relatively higher levels than the rEDIII-4 protein. This was consistently observed in multiple experiments; however, the reason is not clear. We observed two conservative amino acid changes outside domain III in the gene encoding rEDIII-2, as mentioned in the Materials and Methods. Since both of these proteins are engineered to carry a carboxy-terminal 6× His tag, we next performed a Western blot analysis using the commercially available penta-His MAb, as shown in Figure  2B . Both monovalent proteins were specifically recognized by the penta-His MAb, leading to the conclusion that both the recombinant monovalent genes can be successfully expressed in E. coli.
Design and expression of a bivalent domain III-based chimeric protein. We created the chimeric gene EDIII-4/2 by in-frame fusion of the two monovalent genes (Figure 1 ). Since the chimeric gene incorporates sequences corresponding to two monovalent genes, we refer to it is as the bivalent gene. Correspondingly, the recombinant protein it encodes, the rEDIII-4/2 protein, is referred to as the bivalent protein. Its amino-terminal half corresponds to the rEDIII-4 protein and the carboxy-terminal half corresponds to the rEDIII-2 protein. A tetrapeptide linker, Gly-Gly-Ser-Gly, joins the two halves. The chimeric EDIII-4/2 gene was inserted in-frame with the initiator codon and a carboxy-terminal 6× histidine tag-encoding sequence of the IPTG-inducible expression vector pQE60 described above. The resultant expression plasmid pQ-EDIII-4/2 is shown in Figure 3A . The induction profile of a typical E. coli clone harboring this construct is shown in Figure 3B . Total lysates (prepared by directly boiling cell pellets in SDS-PAGE sample buffer) were examined in this FIGURE 1. Strategy to create dengue (DEN) EDIII-based bivalent antigen. cDNAs corresponding to the EDIII-encoding regions of the DEN-2 and DEN-4 genomes (indicated by the solid black and gray lines, respectively) were obtained by reverse transcription-polymerase chain reaction (steps A and C), using specific primers (see Table 1 ). The resultant cDNA products (indicated by the boxes labeled 2 and 4) were designed to have Bgl II and Bam HI at the 5Ј and 3Ј ends, respectively. The DEN-2 and DEN-4 EDIII cDNAs (2 and 4), carrying Taq polymersae-added 3Ј adenylic acid residues (indicated by the As), were inserted into the TA cloning vector pGEMT-Easy (steps B and D), to generate the constructs pT-2 and pT-4, respectively. The DEN-2 EDIII cDNA was retrieved from pT-2 as a Bgl II/Bam HI fragment and inserted into the Bam HI site of pT-4 (step E). In the resultant construct, pT4-2, the DEN-2 EDIII cDNA is fused in-frame to the 3Ј end of the DEN-4 EDIII cDNA. B/B denotes the Bgl II/Bam HI fusion site GGATCT, encoding Gly-Ser. also appears that there was no significant non-specific binding to the affinity matrix. This is consistent with virtually no protein appearing in the wash fractions (lanes 4 and 5). Elution with a pH 4.5 buffer resulted in the emergence of highly purified recombinant protein from the column (lanes 6-9). From a comparison of the protein profiles of the eluted material (for example, lane 6) and the crude lysate (lane 2), it is clearly evident that > 95% purity has been obtained.
We tested the purified chimeric protein in a Western blot assay using different antibodies to confirm its identity. To this end, we prepared a blot containing the affinity-purified bivalent protein and its monovalent precursors. We also included in this blot a previously described DEN-2 EDIII-based recombinant protein variant as a positive control. This variant also includes upstream amino acid sequences in addition to a 6× His tag. 23 Consequently, it is larger (approximately 19 kD) and is referred to as rEDIII-2* in this report to distinguish it from the approximately 14 kD rEDIII-2 generated in the present study. This blot was probed with a commercially available murine penta His MAb that was specific for the engineered 6× His Tag on the recombinant proteins. The results showed that the penta His MAb, which can specifically recognize the r-EDIII-2* control protein, 23 also recognized the approximately 28-kD bivalent protein, which is consistent with its ability to bind to the Ni-NTA matrix. In this immunoblot, the penta His MAb also recognized the monovalent protein precursors because they also carried the 6× His tag. We repeated the Western blotting experiment with murine polyclonal antibodies elicited by the rEDIII-4/2 protein. The results of this experiment are shown in Figure 4B . As expected the murine antibodies recognized the rEDIII-4/2 protein (lane 4). The murine antibodies to rEDIII-4/2 also recognized the rEDIII-2 (lane 2) and rEDIII-4 (lane 3) proteins. This observation is consistent with the design of the bivalent protein, which is derived from these two monovalent precursor proteins. Once again, the previously characterized rEDIII-2* protein served as a corroborating control (lane 5).
Starting with approximately 1.5 grams of induced cell pellet (equivalent to 500 mL of E. coli culture), we obtained approximately 14 mg of purified recombinant protein (pooled fractions in lanes 6-9). We recently described the use of a sandwich ELISA protocol designed for the specific detection of the 6× His-tagged rEDIII-2* protein mentioned in conjunction with the DEN-2 envelope EDIII-specific MAb 3H5. 23 We had shown that in this assay an unrelated 6× Histagged recombinant protein or an untagged E protein (provided by DEN-2 virus) did not elicit any significant antibody response. We adapted this assay for the detection and quantitation of the rEDIII-4/2 bivalent protein. In this assay, the 6× His-tagged bivalent protein in total lysates or in column fractions was captured in Ni-NTA HisSorb microtiter wells and then allowed to react with DEN-2 EDIII-specific 3H5 MAb. The resultant Ni-NTA-immobilized bivalent antigen/ 3H5 MAb complex was detected using anti-mouse IgG-HRPO conjugate. Using this sandwich assay, we estimate that our purification resulted in approximately 27% recovery. This assay clearly demonstrates the presence of the DEN-2 EDIII component in the bivalent protein. Ideally, this sandwich ELISA should also have been done using a DEN-4 EDIIIspecific MAb instead of the 3H5 MAb. This would have independently demonstrated the presence of the DEN-4 EDIII component in the bivalent protein. However, the lack of such a DEN-4 EDIII-specific MAb precluded this assay. We therefore raised murine polyclonal antibodies to the monovalent precursor proteins rEDIII-2 and rEDIII-4 to address this issue.
Retention of the antigenic identities of its precursors by rEDIII-4/2 protein and formation of antibodies with preferential specificity for its constituent serotypes. A major objective of this study was to explore if a chimeric EDIII-based dengue virus antigen would retain the antigenic identities of its precursors. In other words, would the rEDIII-4/2 protein manifest the antigenic characteristics of its monovalent EDIII precursors? To address this question, we examined the reac- tivity of the rEDIII-4/2 protein towards antisera raised against the monovalent rEDIII-2 and rEDIII-4 proteins. For comparison, we also generated antisera to rEDIII-1 and rEDIII-3 as well (all four monovalent proteins were expressed and purified using protocols described for the rEDIII-4/2 protein as described in the Materials and Methods). In the experiment shown in Figure 5A , serial dilutions of murine antisera raised against each of the four monovalent recombinant EDIII proteins were titrated against the rEDIII-4/2 protein as the capture antigen. We also tested in this experiment the reactivity of the rEDIII-4/2 protein towards anti-rEDIII-4/2 antiserum and serum from mock-immunized mice as positive and negative controls, respectively. The data show that the rEDIII-4/2 protein displayed high levels of ELISA reactivity towards anti-rEDIII-2 ( Figure 5A , curve e) and anti-rEDIII-4 ( Figure 5A, curve d) antisera. The magnitude of the ELISA reactivity towards these two antisera was equal to that displayed by the rEDIII-4/2 protein towards antiserum raised against itself ( Figure 5A, curve f) . In striking contrast, the rEDIII-4/2 protein manifested significantly lower reactivity towards anti-rEDIII-1 ( Figure 5A , curves f and b) and antirEDIII-3 antisera ( Figure 5A , curve c). In comparison with the anti-rEDIII-2 and anti-rEDIII-4 antisera, the antirEDIII-1 and anti-rEDIII-3 antisera displayed consistently lower (approximately three-fold) ELISA titers in the linear range of the dose-response curves (coinciding with serum dilutions in the range 1:4,000-1:8,000). These data suggest that the bivalent rEDIII-4/2 protein retains the antigenic properties of its monovalent precursors. This leads to the prediction that antibodies induced by the bivalent protein would be capable of specifically recognizing and binding to both rEDIII-2 and rEDIII-4 proteins.
We next did the converse experiment to test the above prediction. In this experiment, we used rEDIII-2 and rEDIII-4 as capture antigens and performed an ELISA using serial dilutions of anti-rEDIII-4/2 antiserum. We also used rEDIII-1 and rEDIII-3 proteins as coating antigens for comparison. As before, rEDIII-4/2 protein-coated wells were used as a positive control. As a negative control, mockimmunized serum was tested using a mixture of the four monovalent rEDIIIs as the capture antigen. The data are shown in Figure 5B . The data demonstrate that the reactivities of anti-rEDIII-4/2 antiserum towards rEDIII-2 ( Figure  5B , curve d) and rEDIII-4 ( Figure 5B , curve e) proteins are similar to each other over the entire range of dilutions tested. Conversely, ELISA titers observed using either rEDIII-1 ( Figure 5B, curve b) or rEDIII-3 ( Figure 5B , curve c), which were comparable to each other, were significantly lower than those seen for the rEDIII-2 and rEDIII-4 proteins. Again, these ELISA titers were consistently lower (approximately three-fold) when compared with those for the rEDIII-2 and rEDIII-4 proteins. These data suggest that the rEDIII-4/2 protein has the potential to evoke a bivalent immune response resulting in the induction of antibodies specific to rEDIIIs of both DEN-2 and DEN-4 viruses.
Specific blocking of the binding of DEN-2 and DEN-4 viruses to host cells and neutralization of their infectivity by antibodies elicited by the bivalent protein.
The ELISA data above showed that the rEDIII-4/2 protein has the capacity to induce a bivalent response targeting rEDIII proteins of DEN-2 and DEN-4 preferentially. However, this does not provide any information regarding the capacity of these antibodies to recognize and bind to infectious virus. We addressed this using an immunofluorescence assay. In this assay, we mixed DEN-2 and DEN-4 viruses separately with antirEDIII-4/2 antiserum (and two different control sera) and FIGURE 5 . Immunoreactivities of the rEDIII-4/2 protein and its antibodies. Antibody titers were determined using an HisSorb enzyme-linked immunosorbent assay (ELISA). HisSorb microtiter wells coated with the appropriate 6×-his tagged rEDIII protein were incubated with serial two-fold dilutions of murine serum (in duplicate). Captured antibodies were detected using anti-mouse IgG-horseradish peroxidase conjugate/3, 3Ј, 5, 5Ј-tetramethylbenzidine substrate. Data points represent the average of two separate ELISAs. A, Sera from mice that were either mock-immunized (curve a) or immunized with the recombinant proteins, rEDIII-1 (curve b), rEDIII-2 (curve e), rEDIII-3 (curve c) and rEDIII-4 (curve d), or rEDIII-4/2 (curve f), were titrated against rEDIII-4/2 protein as the capture antigen. B, Anti-rEDIII-4/2 antiserum was titrated against rEDIII-1 (curve b), rEDIII-2 (curve d), rEDIII-3 (curve c), or rEDIII-4 (curve e) as capture antigens. As in A, serum from mockimmunized mice was used as a control. However, it was titrated against a mixture of all four rEDIII monovalent proteins as capture antigen (curve a). then incubated the virus/serum mixture with BHK cells in culture for one hour to allow adsorption. We then monitored cell-bound viruses by immunofluorescence using serotypespecific murine MAbs in conjunction with anti-mouse IgG-FITC conjugate. The rationale for this experiment was that if the antibodies present in the anti-rEDIII-4/2 antiserum bound specifically and strongly to the virus (presumably to the surface-exposed EDIII region), it might interfere with the ability of the virus to interact with the host cell-surface receptors. The results of this experiment are shown in Figure 6 . Pre-incubation of either DEN-2 or DEN-4 virus separately with sera drawn from mice either before immunization (Figure 6, a and d) or after mock-immunization ( Figure 6 , c and f) resulted in the detection of cell surface-associated virus. Preincubation of DEN-1 and DEN-3 viruses with anti-rEDIII-4/2 antiserum did not interfere with the detection of these viruses. In striking contrast, pre-incubation of these two viruses with the anti-rEDIII-4/2 antiserum resulted in barely discernible immunofluorescence ( Figure 6, b and e) . Presumably, the antibodies elicited by the recombinant bivalent protein had specifically bound to DEN-2 and DEN-4 viruses, thereby effectively preventing them from binding to the host cell surface.
The question we addressed next was will such binding neutralize virus infectivity? To this end, we performed PRNT assays, by plaquing the antibody-incubated DEN viruses on LLCMK2 cells. 
DISCUSSION
Developing a dengue vaccine has been a challenging task because of the need to provide solid and long-lasting immunity to four serotypes without eliciting the potentially fatal ADE response. 8 Since conventional approaches based on live attenuated dengue viruses have not resulted in a licensed vaccine, 9 increasing attention is being focused on recombinant strategies. 10, 11 These approaches, which are geared towards developing monovalent vaccines targeting single DEN serotypes, envisage the creation of a tetravalent vaccine by physically mixing the four monovalent components into a single formulation. To be of practical utility in the resource-poor regions of the world where the disease is endemic, a dengue vaccine has to be cost-effective in addition to being safe and efficacious. In this regard, the development of a vaccine based on a single tetravalent component, be it virus-, plasmid-, or protein-based, would definitely offer a significant cost advantage. Thus, the concept of a single tetravalent dengue vaccine offers an option worth investigating.
The present work is based on the emergence of EDIII as a potential lead candidate for the development of a sub-unit dengue vaccine. We believe that EDIII would be a valuable precursor in developing a tetravalent antigen representing all four serotypes in a single molecule. In a first step towards this objective, we created a chimeric molecule by splicing together the EDIII genes of two different DEN serotypes using a flex- ible linker. It has been shown that in creating chimeric proteins, glycine (because of its lack of a ␤ carbon) and serine (because of its propensity for hydrogen bonding) are preferred linker amino acid residues. 48 Accordingly, we used a Gly-Gly-Ser-Gly tetrapeptide linker to join the two EDIIIs so that they may retain their structural integrity without being subjected to any constraints at the fusion junction. Assembling the bivalent gene in plasmid pQE-60 directly would have necessitated positioning the Bam HI site at the 5Ј end and Bgl II site at the 3Ј end of the monovalent genes to conform to the relative positions of these two sites in the polylinker of this vector. However, the in-frame fusion would have entailed ligation of the 3Ј Bgl II end of one monovalent gene to the 5ЈBam HI end of the other. This would result in the fusion sequence AGATCC coding for Arg-Ser as the internal amino acid residues in the tetrapeptide linker. Since Arg with its bulky and charged side chain in not preferable as a linker residue, 48 we used the intermediate pGEMT-Easy cloning step that allowed us to insert Gly in the linker. We recently used a similar linker successfully to create a chimeric protein encoding multiple dengue epitopes for diagnostic use. 46 The chimeric gene was expressed in E. coli using an IPTG-inducible vector and purified by Ni-NTA affinity chromatography with an yield of approximately 28 mg/liter of culture. The purified bivalent protein could be detected in Western blots using penta His MAb, which is consistent with its ability to bind the Ni-NTA matrix and by murine antisera raised against the monovalent precursor proteins ( Figure  5A ).
Having expressed and purified the rEDIII-4/2 protein, we tested whether it would display antigenic reactivities characteristic of the monovalent EDIIIs it was derived from or would possess an entirely new antigenic phenotype. To do this, we would need serotype-specific antibodies to EDIII. Of the serotype-specific MAbs available commercially, only the 3H5 MAb is known to be specific for DEN-2 EDIII. 49 Therefore, as a prelude to this experiment, we expressed and purified monovalent rEDIII proteins of all four serotypes and used them to raise polyclonal murine sera. We then used the rEDIII-4/2 protein as the capture antigen and determined its reactivity to each of the four anti-rEDIII antisera. This showed that the rEDIII-4/2 protein had much greater reactivity towards anti-rEDIII-2 and anti-rEDIII-4 antisera raised against the precursor proteins from which it was derived (Figure 5A) . Commensurate with the high degree of sequence homology (approximately 65%) among the four rEDIII proteins, the rEDIII-4/2 protein cross-reacted with anti-rEDIII-1 and anti-rEDIII-3 antisera, but at significantly lower levels. Clearly, the rEDIII-4/2 protein displayed a marked preference for antibodies raised against its monovalent precursors. This suggests that the rEDIII-4/2 protein had largely preserved the unique antigenic integrity of its precursors. The prediction that stems from this, that the rEDIII-4/2 protein should potentially be able to elicit antibodies with specificities towards both DEN-2 and DEN-4 rEDIIIs, was borne out in the next experiment. In this experiment, we tested the capacity of the antibodies to rEDIII-4/2 to react with each of the four monovalent rEDIIIs. The results, which mirrored the earlier findings, showed that rEDIII-4/2-induced antibodies reacted preferentially with rEDIII-2 and rEDIII-4 ( Figure  5B ); these antibodies cross-reacted with rEDIII-1 and rEDIII-3, but again at low levels. Cross-reactive titers in both sets of experiments were consistently lower (approximately 3-4-fold). In this regard, it is worth mentioning that similar levels of cross-reactivity were reported using a mixture of the four recombinant EDIIIs (as MBP fusions) to immunize mice. 44 The mutually complementary results in these two experiments reinforced the notion that the rEDIII-4/2 protein can function as a bivalent immunogen eliciting antibodies with specificities for EDIII of DEN-2 and DEN-4.
The question we addressed at this point was would these antibodies also bind DEN-2 and DEN-4 virus? If so, would such binding block virus adsorption to host cells and neutralize virus infectivity? Using an immunofluorescence approach to visualize cell surface-bound virus, we observed that the anti-rEDIII-4/2 antiserum could prevent the binding of both DEN-2 and DEN-4 viruses to the host cell surface ( Figure 6 ). It is likely that because EDIII is involved in host receptor recognition, antibodies elicited by the bivalent protein specifically bind to EDIII on the DEN-2 and DEN-4 virion surface and thereby preclude its binding to host cell surface. This was borne out by PRNT data, which showed that the infectivity of both DEN-2 and DEN-4 viruses could be effectively neutralized by the anti-rEDIII-4/2 antiserum. The PRNT 50 titer, was approximately 1:40 for DEN-2 and 1:80 for DEN-4, whereas it was < 1:5 for DEN-1 and DEN-3 ( Figure 7 ). The PRNT 50 titers reported recently using EDIII-based plasmids were approximately 1:10. 18 In contrast, the EDIII-MBP proteins were reported to elicit much higher levels of neutralizing antibodies. 44 The observed differences are very likely a reflection of the nature of antigen, route of immunization, and most importantly differences in the experimental parameters of the PRNT assay. The PRNT 50 titers Ն 1:10 are considered indicative of protective immunity. 50, 51 In the absence of a good animal model for dengue, neutralizing antibody titers FIGURE 7 . Neutralization of the infectivity of dengue (DEN)-2 and DEN-4 viruses, but not DEN-1 and DEN-3 viruses, by antibodies to rEDIII-4/2. A plaque-reduction neutralization test (PRNT) was performed by infecting LLCMK2 monolayers separately with DEN-1 (D1), DEN-2 (D2), DEN-3 (D3), and DEN-4 (D4) viruses that had been pre-incubated with serial two-fold dilutions of anti-rEDIII-4/2 antiserum. The resultant plaque counts, expressed as percent inhibition of virus infectivity (with reference to the number of plaques generated in the absence of antiserum that was taken to represent 100% infectivity) were plotted as a function of antiserum dilution to determine the antiserum dilution that resulted in 50% neutralization (PRNT 50 titers). Each data point shown represents the mean of four replicate assays and the error bars represent the standard deviation.
are widely accepted as surrogate markers of protective immunity. Our data clearly demonstrate the potential of the rEDIII-4/2 protein to elicit neutralizing, and therefore, presumably protective antibodies against both the DEN-2 and DEN-4 viral serotypes. However, additional studies are needed to assess if the reduced levels of cross-reactivity (to DEN-1 and DEN-3 viruses) observed in our experiments would be significant from the viewpoint of ADE.
In conclusion, we have developed a novel bivalent chimeric protein by fusing the EDIIIs of DEN-2 and DEN-4 viruses using a flexible linker. The recombinant protein was expressed in E. coli and purified to near homogeneity. Data from an ELISA and imunofluorescence and PRNT assays strongly suggest that it retains the antigenic identity of its precursors and elicits neutralizing, and therefore, presumably protective antibodies against the DEN virus serotypes represented in the chimeric molecule. This warrants the exploration of the possibility of creating a single tetravalent antigen incorporating the EDIIIs of all four DEN serotypes. The design of the bivalent protein based on a head-to-tail condensation strategy that relies on Bam HI/Bgl II fusion is compatible with insertion of additional EDIIIs to create a single tetravalent molecule. Coupled with the high expression capacity of the E. coli system and easy one-step affinity purification, this strategy has the potential to lead to the development of a cost-effective tetravalent dengue vaccine.
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